BACKGROUND: In the Phase III 'GRETA' trial 474 women aged ≥70 years with early breast cancer were randomly assigned to surgery plus tamoxifen for 5 years or tamoxifen alone for 5 years. This is a long-term update. PATIENTS & METHODS: Focusing on patients still alive in 2003, outcome end points has been recalculated. RESULTS:Median distant metastases disease-free survival is longer with tamoxifen alone for 5 years; (48.8 vs 37.9 months; p = 0.009). No difference was found in distant metastases rate, disease-free survival, breast cancer and overall survival. CONCLUSION: Primary endocrine treatment until the the best response, followed by minimal surgery and prosecution endocrine treatment for 5-10 years is a suitable option for elderly breast cancer patients. Delayed surgery does not prejudice overall survival.
RCT Entities:
BACKGROUND: In the Phase III 'GRETA' trial 474 women aged ≥70 years with early breast cancer were randomly assigned to surgery plus tamoxifen for 5 years or tamoxifen alone for 5 years. This is a long-term update. PATIENTS & METHODS: Focusing on patients still alive in 2003, outcome end points has been recalculated. RESULTS: Median distant metastases disease-free survival is longer with tamoxifen alone for 5 years; (48.8 vs 37.9 months; p = 0.009). No difference was found in distant metastases rate, disease-free survival, breast cancer and overall survival. CONCLUSION: Primary endocrine treatment until the the best response, followed by minimal surgery and prosecution endocrine treatment for 5-10 years is a suitable option for elderly breast cancerpatients. Delayed surgery does not prejudice overall survival.
Entities:
Keywords:
breast cancer; elderly; primary tamoxifen
Authors: Trevor A Jolly; Grant R Williams; Sita Bushan; Mackenzi Pergolotti; Kirsten A Nyrop; Ellen L Jones; Hyman B Muss Journal: Womens Health (Lond) Date: 2016-01
Authors: Austin D Williams; Cecilia Chang; Elin R Sigurdson; Chih-Hsiung Wang; Allison A Aggon; Maureen V Hill; Andrea Porpiglia; Richard J Bleicher Journal: Ann Surg Oncol Date: 2021-10-11 Impact factor: 5.344